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a b s t r a c t
Background: Depression is the leading cause of disability worldwide and electroconvulsive therapy (ECT)
is the most potent therapy. We investigated the clinical response and regional cerebral blood ﬂow
changes in depressed in patients treated with (ECT) in a repeated longitudinal study.
Method: Forty-nine patients (21 men and 28 women) with a mean age 61 years underwent ECT.
Forty-one patients grading improvement after the initial ECT-series (responder group) were compared
with eight, grading no improvement (non-responder group). The patients underwent neuropsychiatric
ratings, measure of clinical response (deﬁned asZ50% reduction of pre-treatment depression score) and
measure of regional cerebral blood ﬂow (rCBF).
Results: The responder group had an initial 60–82%, and the non-responder group a 30–64% clinical
response throughout the follow-up. The non-responder group showed more reported depression
(p¼ .003), and vegetative anxiety (p¼ .024), with a generally higher left temporal rCBF (p¼ .045).
Limitations: The retrospective approach and the small sample-size.
Conclusion: Patients with no subjective improvement after ECT had lesser objective clinical response,
more sustained reported depression with anxiety features, and higher left temporal rCBF.
& 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
1. Introduction
Electroconvulsive therapy (ECT) is, besides pharmacological
treatment and psychotherapy, an important alternative in the
treatment of major affective disorders. Strong arguments for ECT
are melancholic states with imminent risk of suicide, depressive
stupor and depression not responding to drug treatment and
delirious mania (Fink, 1999).
Some patients, however, have a poor or short-acting response
to ECT (Prudic et al., 1996; Tominaga et al., 2011). Several factors
inﬂuence the clinical response. There may be differences between
treatment response as estimated by the patients and the by
professionals, due to different perspectives. The perceived beneﬁts
are probably based on other considerations than just relief of
certain symptoms, for example patient's experience of anxiety or
memory impairment, especially impaired autobiographical mem-
ory (Coleman et al., 1996; Rose et al., 2003). Also the level of
different symptoms and medication may affect the mental and
physical well-being of the patients (Freeman et al., 1980). The
severity of depressive symptoms has furthermore been strongly
associated with patient reports of memory dysfunction (Coleman
et al., 1996).
Poorer subjective response to ECT has been seen in bipolar
depression versus unipolar depression (Hallam et al., 2009)
although fewer ECT treatments may be required in bipolar patients
compared to unipolar patients to achieve similar clinical beneﬁt
(Agarkar et al., 2012).
Studies have found melancholic depression, older age, the
presence of psychotic symptoms, psychomotor change, suicidal
ideations, catatonia or manic episodes, to be predictors of positive
objective response to ECT (Gupta et al., 2000; Hatta et al., 2007;
Hickie et al., 1996; Mukherjee et al., 1994; Nordenskjöld et al.,
2012; O’Connor et al., 2001; Tominaga et al., 2011). On the
contrary, comorbidity of major depression with personality dis-
order, especially borderline personality disorder, schizoaffective
disorder, or medial temporal lobe atrophy, may predict poor
response to ECT (DeBattista and Mueller, 2001; Feske et al.,
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2004; Nordenskjöld et al., 2012; Oudega et al., 2011; Prudic et al.,
2004).
Cerebral blood ﬂow (CBF) and metabolism have been studied in
different psychiatric conditions with a variety of two and three-
dimensional techniques. A regional cerebral blood ﬂow (rCBF)
technique has been shown to differentiate between different types
of dementia, mood disorder and non-organic psychosis (Risberg,
1980). Measurement of rCBF level and distribution in patients with
affective disorders may show contradictory results depending on
factors such as symptomatology, patient age, and psychopharma-
cological treatment. Often, normal to reduced global CBF and rCBF
abnormalities are seen pre-ECT (Iidaka et al., 1997; Mathew et al.,
1980; Milo et al., 2001; Navarro et al., 2004; Silfverskiöld and
Risberg, 1989) and in objective ECT-responders contradictory
short-term results have been seen. Some studies have shown
decreases, also associated with positive clinical outcome (Nobler
et al., 1994, 2001; Silfverskiöld et al., 1986), and others have found
increases in frontal regions (Milo et al., 2001; Vangu et al., 2003) A
12-month follow-up study after ECT showed normalisation in
frontal rCBF in remitted elderly patients (Navarro et al., 2004).
1.1. Aim of the study
The aim is to study the long-term effects of ECT on clinical
measures and rCBF in patients from graded estimation of the
clinical outcome. We will also investigate the long-term outcome
in relation to the initial treatment response.
2. Methods
2.1. Participants and procedure.
Forty-nine consecutive inpatients that presented long-term data
are included in the study. They were suffering from major depression
(in 1980 diagnosed according to DSM III) (DSM-III, 3rd ed.., 1980),
several with deceptions and delusional traits. They were referred to
ECT in accordance with current guidelines for the time (Fink, 1999).
All patients were under voluntary care at the Psychiatric Department
at the Lund University Hospital, and gave their informed consent to
participate in this study of acute and long term effects of ECT. The
study was approved by the local Ethics and Radiation Safety Commit-
tees at the University of Lund. The patients were included in the study
from 1976 to 1983. They did not show any major neurological deﬁcits,
and were not suffering from severe somatic disorder, chronic psycho-
sis, or addiction.
We have earlier studied the clinical and neurophysiological
effects of ECT in depression (Silfverskiöld et al., 1986; Silfverskiöld
et al., 1987a; Silfverskiöld and Risberg, 1989) and the long-term
outcome in patients who were still alive after 25 years follow-up
(Johanson et al., 2005). At the end of the follow-up investigation
year 2002, ten patients were still alive.
The medical reports include neuropsychiatric investigation and
rCBF before and after ECT and at repeated follow-up investigations.
The study covers a median duration of 3.6 years of follow-up
investigations with sufﬁcient numbers of patients in the groups.
2.2. Electroconvulsive therapy (ECT)
A conventional ECT equipment, (Siemens Konvulsator 622s)
and procedure were used. The equipment produced a peak current
of 0.8 A, and intermittent volleys of four unidirectional pulses of
5 ms. The frequency of the pulses was 50 per sec. and the interval
between the volleys 95 ms. The electrode placement was either
bifronto-temporal (BL) or right non-dominant uni-lateral (RUL) as
described by d Èlia (1970). The choice of electrode placement
during the treatments was made on both experimental and clinical
grounds. For inducing anaesthesia we used Atropine (0.5 mg),
methohexital (1 mg/kg), and suxamethone (0.5 mg/kg) which
were injected intravenously. After anaesthesia was induced, 100%
oxygen was given to the patient during average 30 s prior to the
electric stimulus and resumed immediately after cessation of the
visible convulsion and continued until the patient's spontaneous
respiration sufﬁced. The amount of muscle relaxant was chosen so
as to make the switch from the tonic to the clonic phase visible on
the patient's feet. This moment was selected as the starting point
for measuring the seizure duration. The electric stimulus was kept
as low as possible to achieve an adequate (20–60 s) grand mal
seizure (Siemens Joule indicator range between 4 and 9 was used).
The starting point was set as low as possible and increased by one
step when more than 4 s were needed to elicit an adequate
seizure. The treatments were given 2–3 times weekly initially.
When the decision to give ECT was made most non-vital medica-
tions were discontinued (usually three days or more in advance).
Most psychotropic drugs known to interfere with ECT or CBF
pattern were omitted (Silfverskiöld et al., 1987b).
2.3. Neuropsychiatric investigation
The psychiatric evaluations were carried out by the same
psychiatrist at all the investigations. At each follow-up occasion
(II–VI), the treatment result was scored in 7 grades: score 0¼no
improvement; 1¼doubtful improvement; 2¼some improvement;
3¼modest improvement; 4¼moderate improvement; 5¼better
than moderate but not clearly improved; and 6¼clearly improved/
restored (full effect of the ECT treatment). We compare the
patients rating of improvement to a measure of clinical response
deﬁned as a Z50% reduction of the total pre-treatment score on
the reported and observed rating of depression on a rating-scale
for affective symptoms. Patients with improvement (score 1–6)
after the ﬁrst ECT series were deﬁned as responders, and patients
with no improvement (score 0) were deﬁned as non-responders.
We also assessed the number of remissions at each follow-up
occasion. We deﬁned remission as the case when both the
observer and the patient reported relief of depressive symptoms.
The psychiatrist used a semi-structured interview with a
specially designed rating scale, the Rating scale for Affective
Symptoms (RAS scale), developed at the Psychiatric Department
(Eberhard et al., 1965; Nilsson and Smith, 1965).
The RAS scale consists of two sub scales, the depression–mania
scale and the anxiety scale, with reported as well as observed items.
We used the intensity of each symptoms scored in 7 grades: score
0¼no signs of the symptom, to score 6¼constant presence of the
symptom. In this study the clinical analysis was based on 15 items
covering both a depressive and a manic/agitated clinical dimension of
the symptoms reported by the patient and observed during the
interview. In addition there were seven items covering reported and
observed anxiety related symptoms as well as various items describing
reported orientation. The three qualities describing orientation were:
temporal orientation, spatial orientation, personal orientation (own
identity) (the intensity was scored in 7 grades from: none, difﬁculties,
over partial to total disorientation).
For each group of symptoms (reported and observed depressive
dimension, reported and observed manic/agitated dimension,
anxiety groups: vegetative, psychomotor and observed symptoms,
and groups of disorientation) the mean values of the frequency
scores were calculated.
Reported qualities of amnesia for recent events for the time
before the ﬁrst ECT (scored as: none, to more than a week) and
anterograde amnesia from the ﬁrst ECT (scored as: none, to for
most events) were graded after the ﬁrst ECT-series at investigation
II (Table 1).
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The percentage of positive or suspected presence of symptoms
of delusion, paranoia, hallucination, catatonia, confusion and
general disorientation was rated at each points of investigation.
2.4. Regional cerebral blood ﬂow measurement (rCBF)
The rCBF was measured under resting condition in 16 cortical
regions of each hemisphere using a two- dimensional 133Xe
inhalation technique (Meditronic-Novo Diagnostic Systems, Inha-
lation Cerebrographs, Denmark) (Risberg, 1980). In the present
study the initial slope index (ISI) in ml/100 g/min and per cent (ISI
%) was used. ISI, which mainly reﬂects the grey matter blood ﬂow,
has a high reliability (Risberg, 1980). The mean CBF value in each
hemisphere and the global mean ﬂow were corrected for pCO2
(0.75 ISI/mmHg) (Maximilian et al., 1980). The arterial pCO2 was
estimated from end-tidal values of expired CO2 concentrations
while the percentage of ISI was calculated in the frontal and
temporal cortical regions in relation to each hemispheric mean.
The ﬁrst rCBF was recorded immediately before ECT and then
subsequently at the follow-up investigations.
2.5. Data analysis
For the description of variables, results are reported as mean
and standard deviation, medians, per cent and cumulative fre-
quency. We applied the independent sample t-test of means, and
z-test for difference between two independent proportions as
probability tests between patient groups in the demography,
proportions of deceased and the medicated in the groups. Further-
more, Mann–Whitney U-test was used to compare groups at each
investigation in the follow-up variables. We used linear mixed
effects models with repeated measurements on the follow-up
variables, to separate individual random effects from ﬁxed effects
between the groups.
Table 1
Neuropsychiatric investigation: items of analysis.
Reported symtoms of depressive and manic-agitated dimension (frequency scores: 0–6)
Awareness of illness, aggressiveness, need for sleep, psychomotor tempo
Exhaustibility, verbal spontaneity, diurnal rhythm, mood and self-esteem,
Degree of activity
Observed signs of depressive and manic-agitated dimension (frequency scores: 0–6)
Ability of judgement, facial expression, verbal output, psychomotor speed, aggressiveness
Reported and observed anxiety (frequency scores: 0–6)
Vegetative symptoms
Perspiration, dry mouth, palpitations, precordial pain, oppression, breathing difﬁculties
Fainting sensations, weakness of the legs, ﬂushing, dizziness, globus hystericus
Nausea/abdominal churning, urge to urinate and diarrhoea
Psychomotor symptoms
Restlessness, inability to relax, muscle ache, neck ache, head ache
Observed signs
Anxious gaze, tense mimic features, tense body posture, jerky movements, voice pitch, vegetative signs
Orientation and memory function (frequency scores: 0–6)
Time orientation, spatial orientation, own identity
Amnesia for recent events and anterograde amnesia (only graded after the ﬁrst ECT-series)
Table 2
Demography of the patients.
Responders Non-responders
N¼41 M(SD) N¼8 M(SD) U/Zstat p-value1;#
Men 19 2 Z¼1.116 .132
Women 22 6 Z¼1.116 .123
Previous episodes of depression 1.7(1.4) 2.7(2.7) U¼131.0 .360
Onset age of affective disorder 49.8(17.0) 55,7(15.4) U¼137.5 .473
Age of inclusion in study 61.0(12.0) 63.7(15.2) U¼138.0 .482
Previous ECT occasions 4.4(6.9) 4,3(6.7) U¼163.0 .975
First onset to inclusion 11.0(13.2) 8.0(8.7) U¼149.0 .685
Psychiatric diagnoses:
1. MDD 16 3 Z¼0.081 .468
2. MDD with psychotic features 7 1 Z¼0.320 .374
3.Bipol 1 10 2 Z¼0.037 .485
4. Atypical depression 2 1 Z¼0.823 .205
5. Organic affective syndrome 4 1 Z¼0.235 .407
6. Dysthymic disorder 2 0 Z¼0.638 .262
Personality disorder
1. Obsessive–compulsive 0 1 Z¼2.287 .011n
2. Dependant 6 0 Z¼1.155 .124
3. Avoidant 1 0 Z¼0.446 .328
4. Borderline 0 1 Z¼2.287 .011n
5. Passive–aggressive 1 1 Z¼1.316 .094
6. Other personality disorder 14 1 Z¼1.215 .112
Responders (score on reported clinical improvement 40 after ﬁrst ECT-series)
Non-responders (score on reported clinical improvement¼0 after ﬁrst ECT series)
# Difference between patient groups are tested using Mann-Whitney U-test (SPSS) and test for difference between two independent proportions(Openstat):
n po0.05
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3. Results
3.1. Demography of the patients
The sample consisted of 49 depressed patients, 21 men, (M¼55,
SD¼12) years, (range 34–73) and 28 women (M¼66, SD¼11) years
(range 44–83). The 41 patients in the responder group were 19 men,
(M¼57, SD¼12) years (range36–73) and 22 women, (M¼64, SD¼11)
years (range 44–78). In the non-responder group there were 2 men,
(M¼43, SD¼13) years (range 33–52) and 6 women, (M¼71, SD¼8)
years (range 62–83), with women older than men on average. There
were no signiﬁcant differences between the study groups in number
of previous episodes of depression, onset age of affective disorder,
previous number of ECT occasions, or the distribution of psychiatric
diagnosis although among the personality disorders, borderline and
obsessive-compulsive disorder (OCD) struck out in the non-responder
group (Z¼2.287, p¼ .011) (Table 2).
3.2. Follow-up data
From index (I), follow-up investigations proceeded when ﬁrst
ECT-series was ended, at median 14 days after index (II) then at
6 months (III), 15 months (IV), 2.5 years (V) and 3.5 years (VI) after
index. At investigation III, 10 months after index, three patients out
of 41 were deceased in the responder group (of myocardial
infarctions) and two of eight in the non-responder group (one
suicide and one cancer). At the last investigation 20 of 41 patients
in the responder group were deceased (two of suicide and the
rest of heart failure, cancer or strokes), and ﬁve out of 8 patients
in the non-responder group (one suicide, the rest pneumonia,
myocardial infarction and cancer). The difference between the
number of deceased patients in the groups was not signiﬁcant
(Z¼0.710, p¼ .239). The responder group received in average 7.2
(SD¼3.1) number of ECT and the non-responder group 8.3
(SD¼3.5), before the second investigation (U¼132.0, p¼ .382).
Before the second investigation, bi-fronto-temporal (BL) ECT was
used in 31.7% in the responder group and 25% in the non-
responder group, the difference was not signiﬁcant (Z¼0.377,
p¼ . 353). Before investigation VI, the non-responder group
received signiﬁcantly more ECT (M¼9.7, SD¼8.4) than the respon-
ders (M¼1.4, SD¼5,1), (U¼14.0, p¼ .031).
At index (I) and investigation II, 68% of the patients in the
responder group and 75% in the non-responder group were on
psychotropic medication (antidepressants, anxiolytics or neuroleptics).
At investigation IV, and V, higher per cent of the patients in the
responder group were on medication. 67% of the patients were
medicated in both groups at investigation VI. At index (I), 9.7% of
patients in the responder group and 25% in the non-responder group
were on all three medications, and at investigation II, 2.4 %in the
responder group and 12.5% in the non-responder group were on all
three medications. From investigation III, no patient in the non-
responder group was medicated with all three medications, but a
higher per cent was on two medications in the non-responder group.
There were no signiﬁcant differences in the proportion of medicated
patients between the groups at the different investigations I, (Z¼0.377,
p¼ .353), II, (Z¼0.377, p¼ .353), III,(Z¼0.381, p¼ .352), IV,(Z¼0.597,
p¼ .275), V, (Z¼0.455, p¼ .324), VI,(Z¼0.000, p¼ .500).
The grade of improvement and clinical response of the ECT
series in the patients are also listed in the table. The patients in the
responder group showed 58.7% and 58.8% symptom reduction on
reported and observed depression, respectively, after the ﬁrst ECT
Table 3
Follow-up data.
Investigation I II III IV V VI
Time1;# (M/Y) 0 0.5(1.5) M 6.0(10.0) M 15.0(30.5)M 2.6(2.9) Y 3.6(1.5) Y
Responder deceased † 0/41 0/41 3/41 6/41 7/41 20/41
Nonresponders deceased† 0/8 0/8 2/8 2/8 4/8 5/8
ECT numbers Responders2;## 0 7.273.1 1.374.0 1.373.3 0.872.5 1.475.1
ECT numbers Nonresponders2;## 0 8.373.5 0.571.2 0 0 9.778.4*
Psychotropic medication responders (%) 68.3 68.3 76.3 63 61.7 67
Antidepressants 9/41(22) 13/41(31.7) 23/38(60.5) 13/35(37.1) 12/34(35.3) 8/21(38.1)
Anxiolytics 23/41(56.1) 18/41(43.9) 14/38(36.8) 12/35(34.3) 12/34(35.3) 10/21(47.6)
Neuroleptics 12/41(29.3) 8/41(19.5) 8/38(21) 8/35(22.9) 9/34(26.5) 5/21(23.8)
Psychotropic medication nonresponders (%) 75 75 83.3 50 50 67
Antidepressants 3/8 (37.5) 2/8(25) 1/6(16.7) 2/6(33.3) 1/4(25) 1/3(33.3)
Anxiolytics 5/8(62.5) 6/8(75) 4/6(66.7) 3/6(50) 2/4(50) 2/3(66.7)
Neuroleptics 4/8(50) 4/8(50) 3/6(50) 1/6(16.7) 0/4 1/3(33.3)
Improven/clinical response: responders
Subj improve grade – 4.771.4 [40] 4.971.8 [36] 5.571.3 [35] 5.272.0 [26] 5.771.0 [15]
Reported depression 4.670.8 [34] 1.971.6 [38] 1.471.6 [38] 0.871.4 [34] 1.271.9 [31] 0.971.5 [18]
Sympt reduction % – 58.7 69.6 82.6 73.9 80.4
Observed depression 3.471.8 [39] 1.471.8 [41] 1.171.3 [38] 0.671.0 [35] 1.171.8 [31] 0.671.4 [18]
Sympt reduction (%) – 58.8 67.6 82.4 67.6 82.4
In remission – 16/41(39) 22/38(58) 31/35(88.5) 22/34(65) 14/21(67)
Improvem/Clinical response: Nonresponders
Subj improve grade – 0 [8] 1.271.3 [6] 3.673.3 [5] 4.073.5 [3] 4.072.0 [3]
Reported depression 4.870.3 [6] 3.372.0 [8] 2.872.4 [5] 2.672.4 [6] 2.772.7 [4] 2.672.1 [3]
Sympt reduction % – 31.2 41.7 45.8 43.7 45.8
Observed depression 2.571.7 [8] 1.872.0 [8] 2.171.9 [6] 1.472.0 [6] 1.872.5 [4] 0.971.0 [3]
Sympt reduction % – 28.0 16.0 44.0 28.0 64.0
In remission – 0/8(0) 1/6(17) 3/6(50) 2/4(50) 2/3(67)
[ ]¼Number of patients. ( )¼%
Difference between patient groups on ECT numbers are tested using Mann-Whitney U-test,
Difference between deceased patients and the medication, are tested using z-test for difference between two independent proportions.
# ¼Median value (interquartile range).
## ¼Mean and SD.
† ¼Cumulative frequency.
n ¼po .05.
Å. Berggren et al. / Journal of Affective Disorders 167 (2014) 235–243238
series at investigation II. Thirty-nine patients were judged as
being in remission at this occasion. In the non-responder group,
grading no improvement, the symptom reduction on reported
and observed depression showed 31.2% and 28%, respectively.
No patient fulﬁlled the criteria for remission. In the following
investigations, the responder group subsequently reached 82%
symptom reduction with 67% patients in remission, while the
non-responder group at best displayed 64% symptom reduction on
observed depression with two of the three patients in remission at
investigation VI (Table 3).
3.3. Neuropsychiatric scores
Table 4 displays the neuropsychiatric group of symptoms.
Reported depression was initially high in both groups, and was
generally higher in the non-responsive group. At investigation IV
the difference between the groups was signiﬁcantly higher in the
non-responsive group, (U¼50.0, p¼ .037). Reported depression
had a signiﬁcant ﬁxed linear effect (t(47)¼3.081, p¼ .003). The
observed depression followed the reported depression through
the investigation, but to a lesser degree. The reported agitation
was signiﬁcantly higher in the non-responsive group at index
(U¼56.5, p¼ .017) and at investigation VI, (U¼2.5, p¼ .002). The
observed agitation was generally higher in the non-responsive
group except in investigation II. Signiﬁcant difference was noted in
investigation III, (U¼54.5, p¼ .027) and VI, (U¼4.0, p¼ .008).
The ﬁxed difference between the groups was nearly signiﬁcant (t
(47)¼1.975, p¼ .054). Vegetative anxiety was also generally
higher in the non-responsive group, with almost signiﬁcant
difference at index (U¼40.5, p¼ .058) and difference at investiga-
tion IV, (U¼33.0, p¼ .009), with a signiﬁcant group difference
(t(47)¼2.325, p¼ .024). Motor anxiety was as well as vegetative
anxiety was higher in the non-responder group throughout the
follow-up, although not signiﬁcantly different from the responder
group. The observed anxiety dropped initially after the ﬁrst ECT-
series in both groups. In the responders, the level was relatively
constant while the level rises again in the non-responder group
(Table 4).
3.4. Disorientation and memory scores
The time disorientation was initially higher in the responder
group but decreased during the follow-up and in the non-
responder group the trend was initially increasing, and then
generally kept a higher level. The spatial disorientation had a
declining trend in both groups except for a sudden signiﬁcant rise
in the non-responder group at investigation IV (U¼68.0, p¼ .048).
The disorientation as to person was initially higher in the respon-
der group with a declining trend through the follow-up. In the
non-responder group, it was relatively constant except for a rise in
investigation IV, as also the spatial disorientation. This difference
was signiﬁcant (U¼67.5, p¼ .045) (Table 5).
There was no difference between the patient groups with
regards to retrograde amnesia (responders: M¼1.9, SD¼2.0,
n¼39, non-responders: M¼2.1, SD¼2.7, n¼8, U¼149.5, p¼ .849)
or anterograde amnesia (responders: M¼2.1, SD¼1.7, n¼39, non-
responders: M¼1.8, SD¼2.0, n¼8, U¼135.5, p¼ .551) after the
ﬁrst ECT-series at investigation II.
The positive or suspected presence of symptoms of delusion,
paranoia, hallucination, catatonia, confusion and general disorien-
tation was rated at each points of investigation. The presence of
delusion was initially nearly 40% in each group at index, and was
signiﬁcantly higher in the non-responding group at investigation II
(29 versus 5%, U¼107.0, p¼ .041), and III (33 versus 6%, U¼78.0,
p¼ .034), thereafter declining in both groups. Paranoia was initially
20% in the responder group and 13% in the non-responder group,
declining after the ﬁrst ECT-series. Hallucination was sparse in
both groups, though with a peak in the non-responder group at
investigation III (17 versus 0%, U¼87.5, p¼ .016). Catatonia was
present in 10% of responders and 13% at index, after that a decline
was seen. Confusion was rated 13% in both groups at index, then
declining in the responder group but rising in the non-responder
group to 14% and 20% in investigation II and III, respectively, with a
non-signiﬁcant difference. General disorientation was rated 33% in
the responder, and 38% in the non-responder groups at index. The
responder group showed a steady decline in disorientation during
follow-up, but the non-responder group kept the same level at the
follow-up investigations, with a non-signiﬁcant difference.
3.5. Regional cerebral blood ﬂow
The left and right hemispheric mean ISI blood ﬂow was
essentially at the same level at index, with a slight decline after
the ﬁrst ECT-series in both groups, then a steady level through the
follow-up. The per cent frontal rCBF relative to each hemispheric
mean ISI-ﬂow, declined after the ﬁrst ECT-series, kept a lower level
through the investigation relative to index. The right frontal rCBF
was lower in the non-responder group through the follow-up, and
signiﬁcantly lower at investigation III (U¼38.5, p¼ .045). While the
per cent of the temporal rCBF declined bilaterally in the responder
group after the ﬁrst ECT-series, it increased bilaterally in the non-
responder group, and signiﬁcantly on the left side at investigation
II (U¼55.5, p¼ .013), with a signiﬁcant ﬁxed group difference
(t(47)¼2.054, p¼ .045). The temporal rCBF levels were relatively
steady in the responder group but increased in the non-responder
group initially and through the follow-up (Table 6).
4. Discussion
In this study we address the question of the long-term effects
of ECT on clinical measurements and rCBF in the patients graded
estimation of the treatment response and observed clinical
improvement.
In the patients grading improvement after the ﬁrst ECT course,
the clinical response on reported and observed depression was
about 60% while in patients grading no improvement there was
about 30% clinical response. In the following investigations the
response group reached 82% depression reduction and the non-
responders group 64% at best, with a signiﬁcant ﬁxed linear
difference between the groups on the reported depression. There
may be several factors or combinations of these behind the poorer
clinical response in the patients grading no improvement in the
initial ECT series.
There were no differences in demography or distribution of
psychiatric main diagnosis between the patient groups. Although
there was a statistically higher presence of obsessive–compulsive
disorder (OCD) and borderline personality disorders in the non-
responder group, the difference was only one patient in each
disorder in the non-responder group and none of each disorder in
the responder group. It has been suggested that borderline
personality disorder is a distinct separate disorder and that the
depression compared with personality disorder can be effectively
treated with ECT (DeBattista and Mueller, 2001), but others have
found poorer remission after ECT in major depressive patients
with comorbid personality disorder, especially borderline disorder,
also with a prevalence of a higher degree of resistance to
antidepressants (Pfol et al., 1984; Black et al., 1988; Feske et al.,
2004).
Resistance to antidepressant medication may be present in
both groups in our investigation, and Prudic et al. (1996) found,
although marked response to ECT, inferior clinical outcome in
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patients with resistance to antidepressants, while others have
found medication resistance not related to short-term ECT
response (Lam et al., 1999; Pluijms et al., 2002), though Pluijms
et al. (2002) noted a non-signiﬁcantly lower response rate.
In relation to ECT or CBF most medication known to interfere was
omitted, although some patients in both groups were on psychotropic
maintenance medication between the investigations, there were no
signiﬁcant differences in the proportion of medicated patients
between the groups. A difference in the number of ECT between the
groups at investigation VI might imply depression relapse in our non-
responder group. Prudic et al. (2004) showed more frequent relapse in
patients with psychotic depression or comorbid axis I or II disorders as
well as lower sustained remission in ECT-non-remitters.
At index there were higher scores of reported/observed agita-
tion and vegetative anxiety in the non-responder group; these
lowered effectively after the ﬁrst ECT series, though with a
sustained higher motoric anxiety. Throughout the investigation
there was a signiﬁcantly higher ﬁxed effect on the vegetative
anxiety, and a higher but non-signiﬁcant motor anxiety and
observed agitation in the non-responder group. There could be
more underlying anxiety disorders in the non-responder group
and this might explain the dissatisfaction with the initial ECT
treatment, also discussed by Swartz (2009). In contrast
Nordenskjöld et al. (2012) showed in a population based study
that patients with anxiety disorders had a similar responder rate
as patients without such diagnoses.
Table 4
Neuropsychiatric scores (0–6).
Investigation I II III IV V VI
Reported depression
Responder M(SD) 4.5 (0.8) 1.9 (1.6) 1.4 (1.6) 0.8 (1.4) 1.2 (1.9) 0.9 (1.5)
n 34 38 38 34 31 18
Non-responder M(SD) 4.8 (0.3) 3.3 (2.0) 2.8 (2.4) 2.6 (2.4) 2.7 (2.7) 2.6 (2.1)
n 6 8 5 6 4 3
MW-U 73.5 90.0 49.5 50.0 38.5 9.0
Asymptotic p .280 .070 .084 .037n .200 .056
Observed depression
Responder M(SD) 3.4 (1.8) 1.4 (1.8) 1.1 (1.3) 0.6 (1.0) 1.1(1.8) 0.6 (1.4)
n 39 41 38 35 31 18
Non-responder M(SD) 2.5 (1.7) 1.8 (2.0) 2.1 (1.9) 1.4 (1.9) 1.8 (2.5) 0.9 (1.0)
n 8 8 6 6 4 3
MW-U 114.5 142.5 78.5 82.5 55.5 18,5
Asymptotic p .239 .554 .216 .345 .717 .309
Reported agitation
Responder M(SD) 0.08(0.1) 0.1(0.2) 0.2(0.7) 0.4(1.0) 0.04(0.08) 0.06(0.2)
n 33 37 37 33 31 18
Non-responder M(SD) 0.4 (0.4) 0.06(0.1) 0.2(0.2) 0.3(0.8) 0.1(0.2) 0.5(0.3)
n 7 8 5 6 4 3
MW-U 56.5 137.0 55.5 93.5 54.0 2.5
Asymptotic p .017n .690 .099 .772 .526 .002nn
Observed agitation
Responder M(SD) 0.4(0.6) 0.4(0.5) 0.2(0.4) 0.3(0.4) 0.2(0.4) 0.1(0.3)
n 38 38 37 34 31 18
Non-responder M(SD) 0.6(0.4) 0.2(0.2) 0.5(0.3) 0.7(1.0) 0.4(0.4) 0.8(0.4)
n 8 8 6 6 4 3
MW-U 98.0 150.0 54.5 96.0 39.5 4.0
Asymptotic p .107 .950 .027n .797 .203 .008nn
Vegetative anxiety
Responder M(SD) 1.1(0.6) 0.8(0.6) 0.8(0.8) 0.6(0.5) 0.6(0.5) 0.5(0.5)
n 27 38 38 34 30 18
Non-responder M(SD) 1.6(0.4) 1.1(0.7) 1.4(0.9) 1.5(0.8) 1.3(1.1) 0.7(0.1)
n 6 6 5 6 4 3
MW-U 40.5 76.5 53.0 33.0 34.5 11.5
Asymptotic p .058 .199 .111 .009nn .171 .118
Motor anxiety
Responder M(SD) 1.9(1.0) 1.2(1.1) 1.2(1.1) 1.0(1.1) 0.9(0.8) 1.0(1.3)
n 27 38 38 34 30 18
Non-responder M(SD) 1.9(0.9) 1.8(1.0) 2.4(1.4) 1.6(0.8) 1.5(0.9) 2.2(1.5)
n 6 7 5 6 4 3
MW-U 78.0 88.0 45.0 55.0 37.5 12.0
Asymptotic p .888 .156 .056 .073 .226 .124
Observed anxiety
Responder M(SD) 2.3(1.8) 0.9(1.4) 1.0(1.2) 0.7(1.1) 1.3(1.2) 0.9(1.2)
n 39 39 38 35 31 18
Non-responder M(SD) 2.2(1.5) 1.0(1.1) 1.7(1.7) 1.2(1.2) 2.4(1.4) 1.2(1.0)
n 8 8 6 6 4 3
MW-U 149.5 136.0 83.5 70.5 28.0 18.5
Asymptotic p .854 .555 .292 .171 .076 .379
Difference between patient groups are tested using Mann–Whitney U-test,
n ¼po .05.
nn ¼o01.
Å. Berggren et al. / Journal of Affective Disorders 167 (2014) 235–243240
We did not ﬁnd any signiﬁcant differences in disorientation or
memory dysfunction after the initial ECT-series between the
groups. The proportion of BL ECT, with a proposed greater risk to
produce memory dysfunction (Lisanby et al., 2000), did not differ
signiﬁcantly between the groups. Depression per se as well as
retrograde amnesia of autobiographic memory after ECT may have
an impact on the patient's sense of wellbeing (Prudic et al., 1996)
and memory loss after ECT has been reported in 29–79% in
different investigations (Rose et al., 2003) although the conclu-
sions in that study have been questioned (Bergsholm, 2012).
Possibly modern techniques of ECT, i.e. use of brief pulse stimulus,
may have had resulted in less negative effects on cognitive
functions and thereby better wellbeing in the patients.
Both groups showed nearly 40% delusion at index but there was
signiﬁcantly more delusion in the non-responder group in the two
investigations following the initial ECT series. There were also
more hallucinations at investigation III, in the non-responder
group. In a review, Parker et al. (1991) found several features in
common for patients with psychotic (delusional) depression.
There was higher representation of hallucination and psychomotor
disturbance, and patients were often older, had longer duration of
the illness, likely to be hospitalised, to receive combinations of
antipsychotics and antidepressants and to had a poorer course.
Depending on the content of the delusions, these may inﬂuence
the patients grading of the treatment response. Psychotic depres-
sion with delusions is on the other hand a common subtype of
depression considered most treatable with ECT (Birkenhager et al.,
2003; O’Connor et al., 2001). Others have found psychomotor
change, psychotic features, older age, inpatients, suicidal ideation,
and catatonia in melancholic depression without personality
disorders, to be predictors of positive response to ECT (Gupta et
al., 2000; Hatta et al., 2007; Hickie et al., 1996; Mukherjee et al.,
1994; Nordenskjöld et al., 2012; Tominaga et al., 2011).
The left and right hemispheric blood ﬂow was essentially at the
same level at index in both groups, with a slight decline after the
ﬁrst ECT-series, then a steady level through the follow-up. Nobler
et al. (1994) noted a global decrease in CBF in responders versus
non-responders together with lowering in frontal and anterior
temporal regions, averaging 12% in responders. Another study
showed decreased cerebral glucose metabolism in widespread
regions; frontal, parietal, left temporal, anterior and posterior
cingulate gyrus in signiﬁcantly improved patients after ECT
(Nobler et al., 2001). A similar pattern of CBF decrease in frontal
and anterior temporal regions has also been shown in patients
responding to antidepressants (Nobler et al., 2000). Others have
found a normalisation of hypo-perfused frontal and temporal
regions in responding patients after ECT (Milo et al., 2001;
Vangu et al., 2003; Navarro et al., 2004). The frontal rCBF declined
in both our groups after the initial ECT-series, with a lower level
through the investigation relative to index, and the right frontal
level was even lower in the non-responder group. The temporal
rCBF declined somewhat bilaterally in our responder group but
increased in the non-responder group, with a ﬁxed signiﬁcant
group difference on the left temporal region, through the inves-
tigation. Smith et al. (2009), investigating geriatric depression,
used measures of Hamilton Depression Rating Scale (HDRS) and
Hamilton Anxiety Rating Scale (HARS), magnetic resonance ima-
ging (MRI) and Positron emission tomography (PET). The investi-
gators found a positive correlation between depression and
anxiety, and cerebral glucose metabolism in several anterior
cortical regions including left superior and inferior temporal gyrii.
They also showed the areas of increased metabolism correspond-
ing to areas of cerebral atrophy in the patients relative to controls,
discussing a compensatory hypermetabolism. In depressed elderly
with structural abnormalities in the brain, Oudega et al. (2011)
showed that patients with medial temporal lobe atrophy, but not
white matter hyperintensities or global cortical atrophy, presented
poorer response to ECT.
A subset of our patients may have developed organic brain
pathology in the course of the investigation and variations of the
CBF and clinical values in our patients may also be explained by
factors such as sample-size, medication and clinical heterogeneity
with respect to aetiology, pathophysiology or symptomatology of
the depression.
Limitations with the study are the retrospective approach and
the small sample-size, making results uncertain. Strength of the
study was the broad spectrum of clinical variables investigated.
In conclusion, patients with no subjective improvement after
the ﬁrst ECT-series had lesser objective clinical response, some
more agitation, higher vegetative and motoric anxiety, and more
Table 5
Disorientation and memory scores (0–6).
Investigation I II III IV V VI
Temporal disorient
Responder M(SD) 1.2(1.7) 1.0(1.4) 0.4(1.1) 0.3(0.7) 0.3(0.8) 0.2(0.9)
n 38 40 37 35 31 18
Non-responder M(SD) 0.9(1.5) 1.0(1.6) 1.0(1.1) 0.5(0.8) 1.3(1.5) 0.3(0.6)
n 8 8 6 6 4 3
MW-U 137.0 153.0 73.5 86.0 39.5 20.0
Asymptotic p .630 .830 .075 .285 .112 .167
Spatial disorient
Responder M(SD) 0.8(1.6) 0.8(1.4) 0.5(1.1) 0.3(0.9) 0.6(1.2) 0.0(0.0)
n 38 40 37 35 31 18
Non-responder M(SD) 0.8(1.5) 0.5(0.8) 0.3(0.8) 1.2(1.6) 0.5(1.0) 0.3(0.6)
n 8 8 6 6 4 3
MW-U 150.5 158.5 106.5 68.0 61.0 18.0
Asymptotic p .954 .960 .824 .048n .944 .014n
Personal disorient
Responder M(SD) 1.0(1.6) 0.7(1.3) 0.4(1.0) 0.3(0.9) 0.2(0.6) 0.0(0.0)
n 38 40 37 35 31 18
Non-responder M(SD) 0.4(0.8) 0.4(0.7) 0.5(0.8) 1.0(1.1) 0.5(1.0) 0.3(0.6)
n 7 8 6 6 4 3
MW-U 116.0 153.0 96.0 67.5 53.5 18.0
Asymptotic p .532 .804 .459 .045n .469 .014n
Difference between patient groups are tested using Mann–Whitney U-test,
n po .05
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presentation of psychotic features early after the start of treat-
ment. There were possible a higher frequency of depression
relapse and a generally increased left temporal rCBF, in contrast
to patients grading improvement with an initial 60–80% clinical
response after three years. This study shows foremost the relation
between subjective improvement and clinical response after ECT
over a timeline.
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